Search
Now showing items 1-2 of 2
PD-L1 testing by immunohistochemistry in Immuno-Oncology.
(
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
, 2022 , Article Review)
Immunotherapy, based on immune checkpoint inhibitors targeting the Programmed cell death ligand 1 (PD-L1) and/or Programmed Death Receptor 1 (PD-1), has substantially improved the outcomes of patients with various cancers. ...
Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group
(
Academy of Sciences and Arts of Bosnia and Herzegovina
, 2022 , Article)
In the present review, we briefly discuss the breakthrough advances in precision medicine using a tumor-agnostic approach and focus on BRAF treatment modalities, the mechanisms of resistance and the diagnostic approach in ...